Vol. 3 No. 5 (2023)
Reimbursement Reviews

Finerenone (Kerendia)

Published May 18, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses finerenone (Kerendia) tablets, 10 mg and 20 mg, oral administration.
  • Indication: As an adjunct to standard of care therapy in adults with chronic kidney disease and type 2 diabetes to reduce the risk of:
    • end-stage kidney disease and a sustained decrease in estimated glomerular filtration rate
    • cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure